Mucin 1 (MUC1) PAM4 epitope (MUC1-PAM4)

The Tumor-associated PAM4 epitope on MUC1 is a highly specific glycoform of the Mucin 1 protein that is predominantly expressed in pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions, such as pancreatic intraepithelial neoplasia (PanIN) (Gold et al., 2007). While historically associated with MUC1, some research suggests the PAM4 antibody may also recognize specific glycoforms of MUC5AC, though it remains a hallmark target for pancreatic cancer (Gold et al., 2013). Unlike the ubiquitous expression of normal MUC1 in various epithelial tissues, the PAM4 epitope is characterized by a unique glycosylation pattern or conformational change that makes it nearly exclusive to pancreatic malignancies (NIH, 2013). MUC1 is a large transmembrane glycoprotein that normally provides a protective and lubricating barrier on epithelial surfaces, but the PAM4-reactive variant is implicated in oncogenic signaling and cell adhesion in the tumor microenvironment (Amerigo Scientific, 2024). This high specificity makes it an ideal target for both diagnostic imaging and therapeutic interventions, particularly in a disease often diagnosed at advanced stages (NCI, 2024). Therapeutic strategies targeting this epitope include radioimmunotherapy, such as Clivatuzumab tetraxetan labeled with Yttrium-90, which delivers localized beta radiation to tumor cells (Wikipedia, 2023). Experimental approaches also include CAR-T cell therapies designed to recognize this specific MUC1 variant, aiming to provide a more targeted immune response against pancreatic cancer (Tandfonline, 2024).

Other names

PAM4-reactive MUC1Clivatuzumab epitopePancreatic cancer-associated mucinhPAM4 epitopePAM4-reactive MUC5AC

Targeted delivery of radioisotopes (Radioimmunotherapy) or cytotoxic agents to MUC1-expressing tumor cells, or direct T-cell mediated killing via CAR-T cells.